Logo

New Products: Exiqon’s LNA LongRNA Gapmers

Mar 21, 2013
Premium

Exiqon has introduced LNA longRNA gapmers, a collection of RNase U-activating antisense oligonucleotides for the specific inhibition of mRNA and long non-coding RNAs in vitro and in vivo.

According to the company, the oligos offer high affinity and stability with low toxicity and reduced off-target effects.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Drug Discovery & Development
Tools & Technology
RNAi
antisense
LNA
Qiagen
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.